Clinical trial · Observational
Clinical and Economic Impact of Herpes Zoster in Cancer Patients
Clinical and Economic Impact of Herpes Zoster in Cancer Patients - A Retrospective Cohort Study in a Brazilian Cancer Center
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Herpes zoster (HZ) is an important infectious complication among patients with cancer, particularly in the setting of treatment-related immunosuppression. This retrospective observational cohort study aimed to characterize the clinical profile of HZ episodes and estimate direct hospital costs associated with emergency department visits and hospitalizations in patients with active malignancy treated at a Brazilian tertiary cancer center. The study also explored associations between cancer characteristics, recent oncologic therapies, and clinical outcomes, including postherpetic neuralgia, recurrence, disease dissemination, and hospital costs. Findings are intended to support future budget impact and cost-effectiveness analyses of herpes zoster vaccination in oncology populations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Herpes Zoster | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Herpes Zoster episode | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with Herpes Zoster and Active Cancer
- description
- Adult patients with active solid or hematologic malignancies who presented with a clinically confirmed episode of herpes zoster between September 2019 and December 2024 at A.C. Camargo Cancer Center, São Paulo, Brazil.
- interventionNames
- Other: Herpes Zoster episode
Primary outcomes (2)
- measure
- Clinical characteristics of herpes zoster episodes
- timeFrame
- September 2019 through December 2024
- description
- Characterization of herpes zoster episodes in adult patients with active cancer, including clinical presentation, dissemination, postherpetic neuralgia, recurrence, cancer type and stage, and recent oncologic therapies.
- measure
- Direct hospital costs
- timeFrame
- September 2019 through December 2024
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults (≥18 years). * Active solid or hematologic malignancy. * Evaluation at A.C. Camargo Cancer Center (São Paulo, Brazil) between September 2019 and December 2024. * Clinically confirmed episode of herpes zoster (initial episode or recurrence). * Herpes zoster diagnosed based on a typical painful dermatomal rash with polymorphic lesions (macules, papules, vesicles, and crusts), either localized or disseminated. Exclusion Criteria: * Age \<18 years. * No evidence of active malignancy (complete remission or no oncologic treatment for at least one year). * Patients in whom herpes zoster was not confirmed after medical record review.
References
Publications (0)
Data not yet available